

THE UNITED STATES PATENT AND TRADEMARK OFFICE

David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Jr., and

Hai U. Wang

Application No.:

09/988,496

Group:

1614

Filed:

March 4

November 20, 2001

Examiner:

Unknown

For:

ARTERY SMOOTH MUSCLE-AND VEIN SMOOTH MUSCLE-SPECIFIC

PROTEINS AND USES THEREFOR

| CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on March 2003 Signature |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Linda M Crawford |
| Typed or printed name of person signing certificate |
| |

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202


| Sir: | |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| This Ir | information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) |
| [X] | under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). |
| [] | under 37 CFR 1.97(c) together with either: |
| | [] a Statement under 37 CFR 1.97(e), as checked below, or |
| | [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) |
| [] | under 37 CFR 1.97(d) together with: |
| | [] a Statement under 37 CFR 1.97(e), as checked below, and |
| | [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) |
| [] | under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee) |

| Staten | nent Un | der 37 | CFR 1.97(e) | | | | | | |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|
| [] | any co | mmuni | information contained in this Information Disclosure Statement was first cited in cation from a foreign patent office in a counterpart foreign application not more onths prior to the filing of this Information Disclosure Statement; or | | | | | | |
| [] | No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. | | | | | | | | |
| Staten | nent Un | der 37 (| CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 | | | | | | |
| [] | comm was no | unication ot receiv | information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication yed by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement. | | | | | | |
| [X] | Enclos | sed here | with is form PTO-1449: | | | | | | |
| | [X] | Copies AR5-A | s of the cited references AL-AN, AR-AZ, AR2-AZ2, AR3-AZ3, AR4-AZ4 and AZ5 are enclosed. | | | | | | |
| | [] | Applic | opies of cited references are enclosed except those entered in prior application, U.S. pplication No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier oplication contains copies of the cited references.] | | | | | | |
| | [] | sted references were cited in the enclosed International Search Report in a rpart foreign application. | | | | | | | |
| | [] | The "c under . | oncise explanation" requirement (non-English references) for reference(s) [] 37 CFR 1.98(a)(3) is satisfied by: | | | | | | |
| | | [] | the explanation provided on the attached sheet. | | | | | | |
| | | [] | the explanation provided in the Specification. | | | | | | |
| | | [] | submission of the enclosed International Search Report. | | | | | | |
| | | [] | submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action. | | | | | | |
| | | [] | the enclosed English language abstract. | | | | | | |

| [] | A | pplic | ant requests that the following n | on-published pending applic | cations be considered: | | | | |
|------------------------|-------------|----------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------------|--|--|--|--|
| Examiner's Initials | | | | | | | | | |
| | | | U.S. Patent Application No. [|], by [inventor(s)], filed [|], Docket No.: [] | | | | |
| | | | U.S. Patent Application No. [|], by [inventor(s)], filed [|], Docket No.: [] | | | | |
| | | | U.S. Patent Application No. [|], by [inventor(s)], filed [|], Docket No.: [] | | | | |
| | | | Examiner | Date | _ | | | | |
| | [|] | A copy of each above-cited app | lication, including the curre | nt claims, is enclosed. | | | | |
| | [|] | A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed. | lication, including the curre on, U.S. Application No. [| nt claims, is enclosed, except], to which priority under | | | | |
| The E | xan nces | niner s wer | is requested to return a copy of re considered with the next office | the above list of pending apple communication. | plications indicating which | | | | |
| It is re | que | ested | that the information disclosed h | erein be made of record in the | his application. | | | | |
| Metho | d o | f pay | ment: | | | | | | |
| [] | | | k for the fee noted above is encl panying Reply. A copy of this S | | cluded in the check with the | | | | |
| [] | | ease clos | charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is ed. | | | | | | |
| [X] | Pl | ease | ase charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380. | | | | | | |
| | | | R | Respectfully submitted, | | | | | |
| | | | Н | IAMILTON, BROOK, SMI | TH & REYNOLDS, P.C. | | | | |
| | | | В | w Anne Maig | | | | | |
| | | | _ | Anne I. Craig Registration No.: 32,976 | | | | | |
| | | | | Telephone: (978) 341-0036 | | | | | |
| | | | | Facsimile: (978) 341-0136 | 1 | | | | |

Concord, MA 01742-9133 Dated: 3 4 02

| | • | |
|--|---|--|
| | | |
| | | |
| | | |
| | | |
| | | |



| | | | | • . |
|--|--|---|--|-----|
| | | ; | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | - | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

ID NO.: ::ODMA\MHODMA\IMAHage;28886\;1

|] | 449 REPR | MAR 0 7 2002) | ATTORNEY DOCKET NO. APPLICATION NO. 09/988,496 | | | | | | | |
|-------------------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------|--------------------------------------------------|---------------|--------------------------|--|--|--|
| | NFO | ORMATION DISCLOSURE CITATION IN AN APPLICATION THE TRADE | APPLICANT David J. Anderson, et | al | | | | | | |
| | (Use | March 4, 2002 e several sheets if necessary) | FILING DATE November 20, 2001 | GROUP 1614 | | | | | | |
| | | U.S. | . PATENT DOCUMENTS | | | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | SUB- CLASS | | NG DATE IF OPRIATE | | | |
| | AA | | | <u> </u> | | | | | | |
| - | . AB | | | | | | | | | |
| | | FOREIG | GN PATENT DOCUMENTS | | | | | | | |
| | ļ ' | DOCUMENT NUMBER | DATE | CLASS | SUB- CLASS | TRANS YES | SLATION NO | | | |
| _ | AL | WO 96/26958 | 27 FEB 96 | PCT | | | | | | |
| | AM | WO 99/52541 | 21 OCT 99 | PCT | | | | | | |
| | AN | 0 633 315 A2 | 11 JAN 95 | EPO | | | | | | |
| | AO | | | | | ! ! | | | | |
| | AP | | | | | | | | | |
| | AQ | OTHER DOCUMENTS (Including Au | | | | | | | | |
| | AR | Bennett, B. D., et al., "Molecular Cloning of a Ligand for the EPH-Related Receptor Protein-Tyrosine Kinase Htk," Proc. Natl. Acad. Sci. USA, 92:1866-1870 (1995). Bergemann, A. D., et al., "ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites," Mol. Cell Biol., 15(9):4921-4929 | | | | | | | | |
| | AT | (1995). Stein, E., et al., "Eph Receptors Discriminate Specific Ligand Oligomers to Determine Alternative Signaling Complexes, Attachment, and Assembly Responses," Genes Dev. 12:667-678 (1998). | | | | | | | | |
| | AU | Andres, A-C., et al., "Expr Protein Tyrosine Kinases in Carcinogenesis," Oncogene, | n Mammary Gland Develops | h-Relat ment ar | ced Rea | ceptoi | r | | | |
| | AV | Folkman, J., et al., "Blood Vessel Formation: What Is Its Molecular Basis?" Cell, 87:1153-1155 (1996). | | | | | | | | |
| | | Risau, W., Mechanisms of Angiogenesis, "Nature, 386:671-674 (1997). | | | | | | | | |
| | | Pasquale, E. B., "The Eph Family of Receptors," Curr. Opin. Cell. Biol. 9:608-615 (1997). | | | | | | | | |
| | ^ | Wang, H. U., et al., "Eph F Repulsive Guidance of Trunk Outgrowth," Neuron, 18:383- | k Neural Crest Migration | jands C | an Med Notor I | liate Axon | | | | |
| | AZ (| Asahara, T., et al., "Isola Cells for Angiogenesis," So | ation of Putative Proger cience, 275:964-967(199 | nitor E | Indothe | lial | | | | |
| XAMINE | | | DATE CONSIDERED | | | | | | | |